NCT00506441 - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia | Biotech Hunter

Enrollment

245

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Chronic Kidney DiseaseDialysisHyperphosphatemia

Interventions

DRUG

MCI-196

3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind

DRUG

Placebo

3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind

Trial Locations (39)

Unknown

Glendale

Tempe

Hot Springs

Paragould

Pine Bluff

Fountain Valley

La Mesa

Long Beach

Lynwood

Orange

San Diego

Whittier

Brandon

Hudson

Lauderdale Lakes

Tampa

Augusta

Decatur

Macon

Evanston

Evergreen Park

Fort Wayne

Shreveport

Springfield

Eatontown

Flushing

Springfield Gardens

Allentown

Lewistown

Philadelphia

Columbia

Orangeburg

Sumter

San Antonio

Alexandria

Portsmouth

Richmond

West Allis

San Juan